Berberine Relieves Metabolic Syndrome in Mice by Inhibiting Liver Inflammation Caused by a High-Fat Diet and Potential Association With Gut Microbiota

Jinjin Li1†, Jialin Li2†, Jiajia Ni3,4, Caibo Zhang1, Jianlei Jia1, Guoying Wu1, Hongzhao Sun1* and Shuzhen Wang1

1 School of Life Sciences, Qilu Normal University, Jinan, China, 2 Jinan Zhangqiu District Hospital of Traditional Chinese Medicine, Jinan, China, 3 Research and Development Center, Guangdong Meilikang Bio-Science Ltd., Dongguan, China, 4 Dongguan Key Laboratory of Medical Bioactive Molecular Developmental and Translational Research, Guangdong Medical University, Dongguan, China

Whether berberine mediates its anti-inflammatory and blood sugar and lipid-lowering effects solely by adjusting the structure of the gut microbiota or by first directly regulating the expression of host pro-inflammatory proteins and activation of macrophages and subsequently acting on gut microbiota, is currently unclear. To clarify the mechanism of berberine-mediated regulation of metabolism, we constructed an obese mouse model using SPF-grade C57BL/6J male mice and conducted a systematic study of liver tissue pathology, inflammatory factor expression, and gut microbiota structure. We screened the gut microbiota targets of berberine and showed that the molecular mechanism of berberine-mediated treatment of metabolic syndrome involves the regulation of gut microbiota structure and the expression of inflammatory factors. Our results revealed that a high-fat diet (HFD) significantly changed mice gut microbiota, thereby probably increasing the level of toxins in the intestine, and triggered the host inflammatory response. The HFD also reduced the proportion of short-chain fatty acid (SCFA)-producing genes, thereby hindering mucosal immunity and cell nutrition, and increased the host inflammatory response and liver fat metabolism disorders. Further, berberine could improve the chronic HFD-induced inflammatory metabolic syndrome to some extent and effectively improved the metabolism of high-fat foods in mice, which correlated with the gut microbiota composition. Taken together, our study may improve our understanding of host-microbe interactions during the treatment of metabolic diseases and provide useful insights into the action mechanism of berberine.

Keywords: berberine, metabolic syndrome, gut microbiota, high-fat diet, obesity

INTRODUCTION

With a growing increase in changes in diet, lifestyle and other factors, there has been an explosive epidemic trend of metabolic syndrome characterized by obesity, type II diabetes, non-alcoholic fatty liver disease (NAFLD), and atherosclerosis (Ley et al., 2006; Turnbaugh et al., 2006; Zhang H. et al., 2010). As one of the most serious diseases threatening public health (Haslam and James, 2005;
Moustafa and Froguel, 2013; Hall et al., 2015), metabolic syndrome can also cause other diseases, such as NAFLD, which can further develop into steatohepatitis, liver fibrosis, cirrhosis, liver cancer (Osborn and Olefsky, 2012; Yoshimoto et al., 2013; Ni et al., 2021), diabetes, or hypertension and cause multiple organ damage (Thandavarayan et al., 2011; Mozaffari-Khosravi et al., 2012; Wada et al., 2012). Although various drugs are available to treat metabolic syndrome and its complications in the clinical setting, there is presently no specific treatment for this condition (Zhang et al., 2012, 2015; Chang et al., 2015). For example, although metformin and acarbose can reduce blood sugar, its gastrointestinal side effects make it impossible for many patients to tolerate the maximum dose. While thiazolidinediones (TZDs) can reduce insulin resistance, it also causes weight gain and hypoglycaemia (Srinivasan et al., 2015). Therefore, exploring the methods and mechanisms for prevention and treatment of metabolic syndrome has important theoretical and clinical application value.

Metabolic syndrome is typically accompanied by low-level, systemic chronic inflammation, leading to impaired insulin activity and the development of metabolic abnormalities (Boulangé et al., 2016; Reilly and Saltiel, 2017). It has been reported that the activation of inflammation effector molecules contributes to the desensitization of insulin signaling pathways (Ribes-Navarro et al., 2019). At the molecular level, the activation of IkB kinase complex, extracellular signal-regulated protein kinases 1 and 2 (ERK1/2), and c-Jun N-terminal kinases (JNKs) in the inflammatory tissues of obese individuals can reduce insulin receptor substrate (IRS) protein tyrosine phosphorylation levels, leading to the attenuation of the insulin signal (Tanti et al., 2012). Furthermore, the production of cytokines, such as tumor necrosis factor alpha (TNF-α), in rodent and human visceral adipose tissues regulates insulin sensitivity by altering the expression levels of genes encoding insulin receptor 1 (IRS-1), glucose transporter GLUT4, and PPAR-α (Larsen et al., 2007; Tack et al., 2012). In turn, the loss of insulin sensitivity can trigger fasting hyperglycemia and increase liver lipid synthesis and fat accumulation (Saltiel and Kahn, 2001; Delarue and Magnan, 2007). These responses enhance chronic low-grade inflammation, induce the recruitment and activation of various mature immune cells (including mast cells, macrophages, and dendritic cells) and adipocytes in metabolic tissues, and ultimately, further augment the inflammatory response (Lumeng and Saltiel, 2011; Sell et al., 2012).

Various microorganisms inhabit the intestines of vertebrates. Cooperatively, the gut microbiota play an important role in the growth, development, metabolism, and immunity of the host (Turner, 2009; Levy et al., 2017; Cani et al., 2019; Seth et al., 2019; Ruff et al., 2020). Additionally, recent studies have demonstrated that gut microbes play an important role in the occurrence and development of metabolic diseases such as obesity, insulin resistance, atherosclerosis, and NAFLD (Cani et al., 2007). Gut microbiota help break down hard-to-digest food components, such as dietary fiber (Qin et al., 2010), and can also regulate the metabolism of bile acids, lipids, and amino acids in the host by exchanging metabolites with the host and participating in signal pathways and regulating the host gene expression and energy homeostasis (Bäckhed et al., 2004; Turnbaugh et al., 2006; Velagapudi et al., 2010). However, structural imbalance of the gut microbiota due to high-fat diet (HFD) intake may damage the intestinal barrier, thereby leading to increased levels of inflammatory factors and lipopolysaccharides (LPS) in the circulatory system, which can trigger metabolic inflammation, and subsequently, induce insulin resistance, obesity, and diabetes (Cani et al., 2008). Moreover, gut microbiota imbalance, particularly a reduction in the abundance of Bifidobacterium spp, that protect the intestinal barrier function and an increase in the abundance of pathogenic bacteria such as Desulfovibrio spp, that produce endotoxin and H₂S, can compromise the barrier function of the intestine (Zhang et al., 2008). This causes high levels of intestinal toxins such as LPS to enter the circulatory system of the host and induce chronic systemic low-grade inflammation, a condition known as “metabolic endotoxemia.” Eventually, long-term chronic inflammation can lead to a series of metabolic diseases such as decreased insulin sensitivity and NAFLD (Yin et al., 2008a).

Berberine hydrochloride exhibits a modest inhibitory effect on bacteria, fungi, and viruses. Berberine is mainly used clinically to treat intestinal infections and bacterial diarrhea (Hwang et al., 2003; Villinski et al., 2003). In addition, berberine can also be used to treat various metabolic diseases such as diabetes, hyperlipidemia, inflammation, and cardiovascular disease (Li et al., 2008; Yin et al., 2008a,b; Zhang et al., 2008; Zhang C. H. et al., 2010). The anti-inflammatory effects of berberine are primarily linked to the regulation of blood lipids, inhibition of oxidative stress, reduction of cell apoptosis, regulation of cell energy metabolism and inflammatory factor expression, and increased adiponectin levels (Wu and Wang, 2008; Wu et al., 2010). Furthermore, berberine can inhibit the activation and transcription of inflammatory cytokines by suppressing the activation of nuclear factor-kappa B (NF-κB), thus displaying activity against metabolic syndrome (Zhu et al., 2018). For example, berberine can reduce the expression of TNF-α, IL-6, and leptin in 3T3-L1 adipocytes (Choi et al., 2018). In addition, berberine plays a role in reducing insulin resistance by inhibiting the phosphorylation of IKKβ (Ser181) and the translocation of NF-κB (P65) into the nucleus (Yi et al., 2008). Since the oral bioavailability of berberine is very low and most of the drug is not absorbed and excreted intact in feces, a major part of the drug can directly interact with the gut microbiota (He et al., 2009). Studies have shown that the gut microbiota-derived metabolites of berberine can inhibit the entry of NF-κB (P65) into the nucleus by downregulating the expression of TLR4 and MyD88, which in turn inhibits the TLR4-MyD88-NF-κB signaling pathway. This indicates that colitis can be alleviated by reducing the expression of related inflammatory factors such as TNF-α, NF-κB, IL-6, and inducible nitric oxide synthase (iNOS; Li et al., 2020). It has been reported that berberine intervention in hamsters with HFD-induced obesity inhibits weight gain and fat deposition; reduces blood sugar, blood lipid, and cellular lipopolysaccharide levels; improves inflammation and insulin resistance; and relieves fatty liver disease and leads to increased production of short chain fatty acids (SCFA; Guo et al., 2019). This indicates that the metabolic regulation mechanism of berberine is likely closely related to...
the gut microbiota status, which represents a potential target for the development of therapeutic drugs. However, whether berberine mediates its anti-inflammatory and lipid lowering effects solely by adjusting the structure of the gut microbiota or by first directly regulating the expression of host pro-inflammatory proteins and activating macrophages and then acting on gut microbiota, is currently unclear. The answer to this question will help clarify the anti-inflammatory mechanism of berberine and provide theoretical guidance for the subsequent development of berberine and antibiotics, or berberine and probiotics for the treatment of metabolic syndrome.

Accordingly, this study used SPF-grade C57BL/6J male mice to construct an obese mouse model and conduct a systematic study on liver tissue pathology, inflammatory factor expression, and gut microbiota structure. We screened the targets of berberine in gut microbiota and showed that the molecular mechanism of berberine activity against metabolic syndrome involves the regulation of gut microbiota structure and expression of host inflammatory factors.

**MATERIALS AND METHODS**

**Animal Models and Experimental Design**

Animal experiments were approved by and performed in accordance with the guidelines of the Animal Ethics Committee of the Qilu Normal University. Sixty male C57BL/6J mice (6 weeks old) were obtained from the Laboratory Animal Center of Shandong Academy of Medical Sciences (Jinan, China) and fed on normal chow diet for 2 weeks to adapt to the environment. Thereafter, animals were divided into six groups (n = 10 per group) as follows: Normal chow diet (NCD group; 10% kcal from fat, Open Source Diets, D12492), HFD supplemented with berberine (100 µg/kg/d body weight was suspended in 0.5% sodium carboxymethyl cellulose solution and fed through gavage; NCDBBR group), high-fat diet (HFD group; 60% kcal from fat, Open Source Diets, D12492), HFD supplemented with berberine (100 µg/kg/d body weight was suspended in 0.5% sodium carboxymethyl cellulose solution and fed through gavage; HFDBBR group), HFD supplemented with antibiotics (HFDBTBBR group), and HFD supplemented with berberine and antibiotics (HFDBBBRRBT group). The mice were treated for 15 weeks, and drank freely during the experiment (Figure 1). To control the influence of the solvent, the same volume of 0.5% CMC-Na used to dissolve berberine was also administered to the NCD and HFD groups. To analyze whether berberine could still reduce fat accumulation and inhibited liver inflammation in mice fed with high-fat diet when the gut microbiota was inhibited by antibiotics, we set two antibiotic-treated groups (i.e., HFDBTBBR and HFDBBRABRT). Antibiotic-treated mice were fed water containing 1 g/L ampicillin, 0.5 g/L vancomycin, 1 g/L neomycin, and 1 g/L metronidazole, all of which were obtained from Solarbio (Beijing, China) (Kamilla et al., 2017). Mice were housed in standard plastic cages (five mice per cage) and maintained under a 12 h light-dark cycle at constant temperature and humidity [23 ± 1°C] and [55 ± 5%], respectively. To record mice body weight, six mice in each group (five mice in the HFDBTBBR group) were randomly weighed weekly at the end of each week.

**Sample Collection**

Mice were sacrificed by cervical dislocation and fixed on a dissecting plate. The abdominal cavity was quickly opened and the liver gently removed. After rinsing with phosphate-buffered saline (PBS), some liver tissues were fixed with 10% neutral buffered formalin for tissue section analysis and the rest were quickly frozen in liquid nitrogen and stored at −80°C until used for RT-PCR analysis. Five replicates of fecal samples were randomly collected from each group of mice and stored at −80°C for subsequent sequence analysis.

**Insulin Sensitivity**

Oral glucose tolerance test (OGTT) and insulin tolerance test (ITT) were performed at the 16th week. Three mice in each group were randomly collected to OGTT and another three mice were used to ITT. Before the OGTT, mice were fasted for 8 h and then administered 2 g/kg body weight glucose orally. Blood glucose levels (BGL) were determined with a glucose meter (Yuwell Medical Equipment Co., Ltd., Jiangsu, China) after 0, 15, 30, 60, 90, 120, and 150 min. Before the ITT, mice were fasted for 4 h and insulin (0.75 U/kg) was injected intraperitoneally. Blood glucose levels were determined, as described above, after 0, 15, 30, 60, 90, 120, and 150 min.

**Histopathological Analysis**

Liver tissue was fixed in 10% neutral buffered formalin; then, it was processed routinely, embedded in paraffin wax, sectioned (4 µm thickness), and stained with hematoxylin and eosin (H&E). Histopathological assessment was conducted using a BX53 + DP26 light microscope (Olympus, Japan) (Lin et al., 2019). Oil Red staining was used to visualize the fat in the tissue, and hematoxylin was used to stain the nucleus. F4/80 immunohistochemical detection was performed to determine the distribution of macrophages in mouse liver.

**Quantitative Reverse Transcription-Polymerase Chain Reaction**

Total RNA was isolated from liver samples using the One-step RT-PCR Kit (TOYOBO, China) according to the manufacturer’s protocol. The concentration of total RNA was determined using a NanoDrop One spectrophotometer (Thermo Fisher Scientific, United States). Then, 1 µg of total RNA was reverse transcribed into cDNA using oligo(dT) primers. Next, qRT-PCR was performed to analyze gene expression using the SYBR Green PCR Master Mix (Tiangen, Beijing, China). The transcriptional levels of target genes were normalized against the mRNA levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Primers for target genes, listed in Table 1, were designed using the Oligo 7.0 Program. The primers were synthesized by the Shanghai Shenggong Biotechnology Co., Ltd. The SYBR®Premix Ex Taq™ was purchased from Takara Biomedical Technology (Beijing) Co., Ltd. The amplification...
FIGURE 1 | Framework shows the main process of the experiment. NCD, normal chow diet; NCDBBR, NCD supplemented with berberine; HFD, high fat diet; HFDBBR, HFD supplemented with berberine; HFDABT, HFD supplemented with antibiotics (by drinking freely); HFDBBRABT, HFD supplemented with berberine and antibiotics. Antibiotic-treated mice were fed water containing 1 g/L ampicillin, 0.5 g/L vancomycin, 1 g/L neomycin, and 1 g/L metronidazole.

Gut Microbiota Composition Analysis
Genomic DNA was extracted using the PowerFecal DNA Kit according to manufacturer's protocols (QIAGEN, Germany). The V4–V5 hypervariable region of prokaryotic 16S rRNA gene was amplified using the universal primers 515F and 909R as previously described (Xiang et al., 2018; Ni et al., 2019). The amplicons were quantified with a NanoDrop 2000 spectrophotometer, and equimolar amounts of each sample were pooled and purified using the AxyPrep DNA gel extraction kit (Axygen, China). The purified DNA fragments were sequenced using an Illumina MiSeq system at Guangdong Melilikang Bio-Science Ltd., China.

Raw reads were merged using the FLASH 1.2.8 software (Magoc and Salzberg, 2011) and processed using the QIIME 1.9.0 pipeline (Caporaso et al., 2010), as previously described (Ni et al., 2017; Huang et al., 2018). Briefly, all merged sequences were trimmed and assigned to each sample based on their barcode sequences with no mismatch. Low-quality and chimera sequences were removed. Subsequently, the sequences were randomly resampled to obtain the same number of sequences in each sample. Then, high-quality sequences were clustered into operational taxonomic units (OTUs) at 97% identity using the UPARSE software (Edgar, 2013). Each OTU was assigned to taxonomic groups using the RDP classifier (Wang et al., 2007) with gg_13_8 dataset. Functional profiles of gut microbiota were predicted using the phylogenetic investigation of communities by reconstruction of unobserved states (PICRUSt; Langille et al., 2013).

Data Analysis
One-way analysis of variance (ANOVA) with Tukey–Kramer post hoc test was conducted using R 2.5.1 (R Core Team, 2013). The Kruskal–Wallis H-test with Welch's post hoc test was conducted using the Statistical Analysis of Metagenomic
Profiles (STAMP) software (Parks et al., 2014). Non-parametric multivariate analysis of variance (PERMANOVA) (Anderson, 2001) was conducted using the vegan package (Dixson, 2003) in R 3.5.1 (R Core Team, 2013). Kruskal–Wallis H-tests to screen significantly different taxa were conducted using the STAMP software (Parks et al., 2014). Principal co-ordinates analysis (PCoA) was conducted using the QIIME 1.9.0 pipeline (Caporaso et al., 2010), and a heatmap profile was drawn using the pheatmap package in R. Differences with \( p < 0.05 \) were considered significant.

**RESULTS**

**Berberine Significantly Alleviates the Weight Gain and Insulin Resistance Induced by a High-Fat Diet**

The body weight of HFD mice was significantly higher than that of NCD mice (one-way ANOVA, \( p < 0.05 \)), whereas the body weight of HFDBBR mice was significantly lower than that of HFD mice in the end of the experiment (Figure 2A and Supplementary Figure 1A). These results indicated that berberine could effectively reduce the weight gain caused by high-fat food. Antibiotic treatment of the mice fed with high-fat diet (HFDBAT group) did not significantly decrease the weight gain in mice relative to that in the HFD group (Figure 2A and Supplementary Figure 1A). The combination of antibiotics and berberine (HFDBATBBR) had the same effect as berberine alone in inhibiting weight gain caused by high-fat diet (Figure 2A and Supplementary Figure 1A).

Oral glucose tolerance test and ITT results showed that at the end of the experiment, the blood glucose levels of HFD mice were significantly (\( p < 0.05 \)) higher than those of the NCD mice, whereas the blood glucose levels of HFDBBR mice were lower than those of HFD mice (Figures 2B,C and Supplementary Figures 1B,C). Moreover, the blood glucose levels of NCD mice treated with berberine were significantly lower than those of NCD mice without berberine treatment (Figures 2B,C and Supplementary Figures 1B,C). These results indicated that berberine could significantly reduce the blood glucose levels and alleviate the insulin resistance in mice.

**Berberine Reduces Fat Accumulation by Inhibiting Liver Inflammation in Mice**

Histochemical analysis of liver tissue sections using Oil Red staining revealed the presence of a large number of red-stained adipocytes in the livers of mice in the HFD group, but not in those of the HFDBBR group (Figure 3). Treatment with compound antibiotics (HFDBAT and HFDBATBBR groups) evidently decreased accumulation of red-stained adipocytes in the livers of mice in the HFD group (Figures 3B,D). These results implied that gut microbiota derived by high-fat diet probably promoted the accumulation of fat in the liver, both berberine and compound antibiotics could relieve the accumulation.

Macrophages and T cells are important immune cells to study phagocytosis, cellular immunity, and molecular immunology (Gordon, 2016; Peterson et al., 2018). Moreover, macrophage recruitment is closely related to the occurrence of fatty liver (Hill et al., 2014; Gordon and Pludemann, 2017). Our results showed that the number of macrophages, which stained brown, was significantly higher in the liver of the HFD group than that in the liver of the NCD group. However, the numbers of macrophages in the HFDBBR and HFDBAT groups were significantly reduced (one-way ANOVA, \( p < 0.05 \); Figure 4). This result indicated that both berberine and compound antibiotics reduced the number of macrophages in the livers of mice fed with an HFD. Analysis of the distribution of T cells in the liver via CD4 immunofluorescence detection revealed that T-cell infiltration in the HFD group was significantly higher than that in the NCD group (one-way ANOVA, \( p < 0.05 \); Figure 5), indicating increased inflammation. In contrast, T-cell infiltrations in the HFDBBR and HFDBAT groups were significantly lower than that in the HFD group (one-way ANOVA, \( p < 0.05 \); Figure 5), indicating that both berberine and compound antibiotics could significantly reduce the liver inflammation caused by HFD.

Gene expression analysis via qRT-PCR showed that the transcription levels of TNF-\( \alpha \) and cox-2 in the HFD group were significantly higher than those in the NCD group (one-way ANOVA, \( p < 0.05 \); Figures 6A,B). Although the transcription levels of TNF-\( \alpha \) and cox-2 in the livers of the HFDBBR group of mice treated with berberine were significantly lower than those in the HFD group (one-way ANOVA, \( p < 0.05 \)). However, the transcription levels of TNF-\( \alpha \) in HFD mice were higher than those in NCD mice (Figures 6A,B). Although the transcription levels of iNOS are usually significantly upregulated during liver inflammation (Menon and Sudheer, 2007), our results showed that HFD and berberine intervention significantly reduced iNOS expression levels (one-way ANOVA, \( p < 0.05 \); Figure 6D).

To detect the polarization direction of macrophages, we tested the expression of related inflammatory factors following macrophage polarization. The results showed that the Arg1 factor, which represents M2 polarization, was significantly upregulated...
FIGURE 2 | Changes in body weight (A) and blood glucose levels of mice detected using oral glucose tolerance test (OGTT) (B), and insulin tolerance test (ITT) (C). HFD, high fat diet group; HFDBBR, HFD supplemented with berberine; HFDBBT, HFD supplemented with antibiotics (by drinking freely); HFDBBTBBR, HFD supplemented with berberine and antibiotics; NCD, normal chow diet; and NCDBBR, NCD supplemented with berberine. *p < 0.05; **p < 0.01; ***p < 0.001. Five replicates are represented by the data.

FIGURE 3 | Liver pathological tissue section stained with hematoxylin and eosin and oil red. Red stain indicates adipocytes. (A) HFD; (B) HFDBBT; (C) HFDBBTBBR; (D) HFDBBTBBR; (E) NCD; (F) NCDBBBR. HFD, high fat diet group; HFDBBR, HFD supplemented with berberine; HFDBBT, HFD supplemented with antibiotics (by drinking freely); HFDBBTBBR, HFD supplemented with berberine and antibiotics; NCD, normal chow diet; and NCDBBR, NCD supplemented with berberine. The upper-right of each histologic photo is a histologic photo with a larger scale.
FIGURE 4 | F4/80 immunohistochemical analysis of the effect of berberine on the number of liver macrophages in mice fed an HFD. Blue stain indicates the nucleus, whereas brown stain marks macrophages. (A) HFD; (B) HFDABT; (C) HFDBBR; (D) HFDABTBBR; (E) NCD; (F) NCDBBR. (G) Boxplots showing significant differences in the percentage of macrophages in the livers of mice in various diet groups. HFD, high fat diet group; HFDBBR, HFD supplemented with berberine; HFDABT, HFD supplemented with antibiotics (by drinking freely); HFDABTBBR, HFD supplemented with berberine and antibiotics; NCD, normal chow diet; and NCDBBR, NCD supplemented with berberine. Different letters above the boxplots indicate significant differences. The upper-right of each histologic photo is a histologic photo with a larger scale.
FIGURE 5 | CD4 immunofluorescence detection showing the effect of berberine on the number of T cells in the livers of HFD mice. Blue stain indicates the nucleus, whereas red stain labels T cells. (A) HFD; (B) HFDABT; (C) HFDBBR; (D) HFDABTBBR; (E) NCD; (F) NCDBBR. (G) Boxplots showing significant differences in the percentage of T cells. HFD, high fat diet group; HFDBBR, HFD supplemented with berberine; HFDABT, HFD supplemented with antibiotics (by drinking freely); HFDABTBBR, HFD supplemented with berberine and antibiotics; NCD, normal chow diet; and NCDBBR, NCD supplemented with berberine. Different letters above the boxplots indicate significant differences. The upper-right of each histologic photo is a histologic photo with a larger scale.
FIGURE 6 | Expression levels of inflammatory factors in liver tissues of mice (A) TNF-α; (B) cox-2; (C) Reg3g; (D) iNOS; and (E) Arg1. The expression levels were determined by qRT-PCR and normalized to mRNA levels of GAPDH. HFD, high fat diet group; HFDBBR, HFD supplemented with berberine; NCD, normal chow diet; and NCDBBR, NCD supplemented with berberine. *p < 0.05; **p < 0.01; ***p < 0.001.

in the HFD group. However, its expression was significantly reduced in the HFDBBR group (one-way ANOVA, p < 0.05), indicating that berberine treatment biased macrophages toward M2 polarization (Figure 6E). Therefore, we speculated that berberine might improve hepatic fatty inflammation by influencing the polarization direction of macrophages.

Berberine Relieves the Disruption in Gut Microbiota Structure Caused by an High-Fat Diet

High-fat diet significantly alters the host gut microbiota structure and metabolism (Leone et al., 2015; Lin et al., 2019; Wang Y. et al., 2019). To clarify whether berberine alleviates liver inflammation and fat accumulation in mice by relieving disruptions in the gut microbiota structure caused by HFD, a total of 5,235,550 high-quality 16S rRNA gene V4–V5 sequences were obtained from 30 mouse stool samples. To eliminate the influence of the sequencing read depth on subsequent interpretation of results, 84,044 sequences were randomly selected from each sample prior to analysis. A total of 11,300 OTUs with 97% similarity were obtained. Except for a few OTUs that contained 0.013 ± 0.002% of all the sequences used for analysis, the majority of OTUs were divided into 25 phyla, among which Bacteroidetes, Deferrribacteres, Firmicutes, Proteobacteria, and Verrucomicrobia were the dominant phyla (Figure 7A). Treatment with compound antibiotics (HFDABT and HFDABTBBR groups) significantly increased the relative abundance of Proteobacteria in the fecal microbiota of mice (Kruskal–Wallis H-test, p < 0.05; Figure 7B), indicating that the compound antibiotics used in this study had the poorest bacterial inhibitory effect against Proteobacteria compared to that against other bacteria. HFD significantly increased the relative abundance of Firmicutes and Deferribacteres in the fecal microbiota of mice, but significantly decreased that of Bacteroidetes (Kruskal–Wallis H-test, p < 0.05; Figure 7B). Compared with that of the HFD group, the relative abundance of Firmicutes in the fecal microbiota of the HFDBBR group was significantly reduced (Kruskal–Wallis H-test, p < 0.05), but was still higher than that of the NCD group. By comparison, the relative abundance of Bacteroidetes was significantly increased, although it was still lower than that in the NCD group (Kruskal–Wallis H-test, p < 0.05; Figure 7B). In addition, the relative abundance of Proteobacteria and Verrucomicrobia was significantly increased in the fecal microbiota of the HFDBBR group compared with that in the NCDBBR group (Kruskal–Wallis H-test, p < 0.05; Figure 7B and Supplementary Figure 2).
Principal co-ordinates analysis based on the composition of fecal microbiota OTUs showed that antibiotic treatment (HFDABT and HFDABTBBR groups) and HFD significantly altered the composition of mice fecal microbiota (PERMANOVA, \( p < 0.05 \); Figure 7C). Antibiotic treatment (HFDABT and HFDABTBBR groups) significantly reduced the number of OTUs, Shannon index, and Simpson index observed in mice fecal microbiota (Kruskal–Wallis \( H \)-test, \( p < 0.05 \); Supplementary Figure 3). In contrast, HFD significantly reduced the number of OTUs observed in the fecal microbiota of mice, but significantly increased the Shannon and Simpson indexes (Kruskal–Wallis \( H \)-test, \( p < 0.05 \); Supplementary Figure 3). The number of OTUs, Shannon index, and Simpson index observed in the fecal microbiota of mice fed on HFD were significantly reduced after berberine intervention (Kruskal–Wallis \( H \)-test, \( p < 0.05 \)). Berberine treatment did not significantly reduce the number of OTUs observed in the fecal microbiota of mice fed on a normal diet (Kruskal–Wallis \( H \)-test, \( p > 0.05 \)). However, berberine treatment significantly reduced the Shannon and Simpson indexes in these mice (Kruskal–Wallis \( H \)-test, \( p < 0.05 \); Supplementary Figure 3).

To further analyze the significant effects of HFD and berberine intervention on the composition of mice fecal microbiota, we conducted a statistical analysis of the dominant bacteria at the genus level. The results revealed significant differences among the 46 dominant bacterial genera detected (Kruskal–Wallis \( H \)-test, \( p < 0.05 \)). Among them, the fecal microbiota of mice fed on an HFD was significantly enriched for Mucispirillum, Odoribacter, Roseburia, Adlercreutzia, Oscillospira, Psychrobacter, Dehalobacterium, AF12, Coprococcus, Ruminococcus, and some unidentified genera (Kruskal–Wallis \( H \)-test with Welch’s post hoc test, \( p < 0.05 \)). These bacteria did not show signs of significant enrichment in the mice fecal microbiota of the HFDBBR group. In contrast, Parabacteroides, Trabulsiella, Sutterella,
**DISCUSSION**

The inflammatory signaling pathway, wherein the transcription factor NF-κB participates, plays a central role in inflammation. As a cell signaling factor of the NF-κB signal transduction pathway, nitric oxide (NO) can participate in multiple physiological processes such as cellular communication, cell apoptosis, and the autoimmune response (Moncada and Palmer, 2001; Tripathi et al., 2007). When NO is expressed at high levels in cells, it can induce the production of inflammatory factors such as TNF-α, IL-1β, and IL-6. In turn, these pro-inflammatory factors can enhance the activity of iNOS and promote further production of NO, resulting in a vicious circle that intensifies the inflammatory response (Aktan, 2004; Nagy et al., 2007). Cox-2 is an inducible gene that is either not expressed or expressed in very low levels in most tissues or cells under normal conditions. However, extracellular stimuli, such as endotoxins and TNF-α, can induce the expression of COX-2 to help it exert its pathophysiological effects, which, in turn, can mediate an inflammatory cascade (Lanes et al., 2000). Reg3γ is an important factor in innate immunity and plays an important role in maintaining the dynamic balance among mammalian gut microbes and protecting the body from pathogen infection. Consistent with previous research (Xin et al., 2014; Wang Y. et al., 2019), we found that HFD successfully induced mice obesity and related metabolic disorders, as indicated by increased fat deposition, insulin resistance, and hepatic steatosis. These signs of metabolic syndrome were effectively improved after berberine treatment. In this study, berberine treatment not only reduced obesity but also considerably decreased the concentration of TNF-α, iNOS, Cox-2, and Reg3γ. The two common characteristics of NAFLD are lipid accumulation in liver cells and elevated production of pro-inflammatory factors by resident or infiltrating macrophages (Stojasavljević et al., 2014). Liver macrophages, among which Kupffer cells derived from embryos are the most common, are dynamic participants in maintaining liver homeostasis (Guilliams et al., 2016). During the occurrence of NAFLD, liver macrophages are polarized, recruited, and proliferated (Meli et al., 2014). Macrophages are polarized across a broad spectrum, from a pro-inflammatory M1-like state, to an anti-inflammatory and pro-fibrogenic M2-like state (Menon and Sudheer, 2007). During infection with intracellular pathogenic microorganisms, macrophages typically show M1 polarization and express the corresponding pro-inflammatory factors to eliminate pathogenic microorganisms. However, in the presence of extracellular pathogenic microorganisms or allergens, macrophages undergo substitution activation (M2) and express Arg1 and other anti-inflammatory factors to promote tissue repair. Therefore, the precise regulation of macrophage polarization is very important for the treatment of metabolic diseases (Li et al., 2019). The chemokines CCL2 and TNF-α, which are secreted by inflammatory liver cells, can cause Kupffer cells to proliferate and polarize toward M1 and express IL-6, IL-1β, TNF-α, and inducible nitric oxide synthase 2 (iNOS2). Macrophages and T cells are important in the study of phagocytosis, cellular immunity, and molecular immunology (Gordon, 2016; Peterson et al., 2018). Moreover, these immune cells are closely related to the occurrence of liver fat metabolism diseases (Hill et al., 2014; Gordon and Pluddemann, 2017). Here, we observed an increased percentage of macrophages and T cells in the HFD group, which was suppressed by berberine treatment. In agreement with these findings, we observed that the expression of Arg1 in HFD mice increased significantly, compared to that in NCD mice, and was efficiently reduced by berberine administration. Studies have shown that excessive calorie intake, increased fat accumulation, and fat toxicity can activate the production of effector molecules (cytokines) and cells that are mainly involved in innate immunity (Cai et al., 2005; Cani et al., 2007). These products can enhance chronic low-grade inflammation and induce the recruitment and activation of various mature immune cells (including mast cells, macrophages, and dendritic cells) and fat cells in metabolic tissues, particularly in adipose tissue, thereby further enhancing the inflammatory response (Lumeng and Saltiel, 2011; Sell et al., 2012). In this study, we found that an HFD hindered fat metabolism in mice livers and increased the inflammatory response. After berberine intervention, these phenomena were significantly improved.

As a “second genome” for modulating the health phenotype of the superorganism host, gut microbiota are closely associated with host nutrition, metabolism, and immunity (Jia et al., 2008; Jin et al., 2020). It has been reported that an HFD disrupts gut microbiota in two ways: via diminishing the levels of gut barrier-protection probiotics such as Bifidobacteria and promoting the growth of endotoxin producers. These changes can result in high levels of lipopolysaccharide (LPS) in the host blood, thereby causing inflammation, and consequently, obesity and insulin resistance (Cani et al., 2007). Studies have reported that the antibacterial activity of berberine in the intestine is related to its anti-obesity effects. Berberine can reduce the entry of intestinal endotoxins into the blood circulation, thereby reducing the level of low-grade inflammation and preventing the development of metabolic diseases (Zhang et al., 2012). Similarly, our results
showed that the LPS producers *Mucispirillum* and *Psychrobacter* (Smith et al., 2017; Herp et al., 2019) were significantly enriched in the HFD group, but not in the HFDBBR group. This result suggested that berberine might play a role in suppressing the inflammatory response by reducing the content of LPS in the blood. It has been shown that *Adlerecreutzia* is a marker of abnormal lipid metabolism (Wei et al., 2018). In addition, a multi-omics analysis of patients with liver steatosis revealed that steatosis is significantly negatively correlated with *Coprococcus* (Alferink et al., 2021). Moreover, it has been reported that *Ruminococcus gnavus* plays an important role in the upregulation of oxidative stress-related gene pathways in the gut microbiota of patients with inflammatory bowel disease (Hall et al., 2017). Our research showed that these bacterial groups were significantly enriched in the HFD group, but not in the HFDBBR group. These findings suggest that berberine can improve lipid metabolism and inflammation by regulating the gut microbiota. Studies have shown that *Parabacteroides* can significantly improve obesity, insulin resistance, lipid metabolism disorders, and NAFLD symptoms in HFD-induced obese mice and in an ob/ob obesity mouse model (Wang K. et al., 2019). Furthermore, it has been reported that *Sutterella* in the intestine of patients with constipation-autistic spectrum disorder is reduced significantly (Dan et al., 2020). Additionally, it has been demonstrated that *Bacteroides* regulates liver lipid metabolism and reduces NAFLD by activating the Bacteroides-folate-liver axis pathway (Qiao et al., 2020). *Akkermansia muciniphila* can ameliorate the negative effect of interferon-γ on glucose tolerance, which is negatively related to obesity, diabetes, cardiovascular diseases, and low-grade inflammation (Greer et al., 2016). We found that these bacterial species were significantly enriched in the HFDBBR group, which indicated that berberine could significantly improve obesity, insulin resistance, lipid metabolism disorders, and NAFLD symptoms.

Studies have shown that SCFA-producing bacteria are beneficial to the host, as they protect the mucosa from pathogen-induced damage, supply colonocyte nutrients, and mitigate inflammation (Maslowski et al., 2009; Filippo et al., 2010).
Together with preventing HFD-induced insulin resistance, berberine also significantly increases the abundance of SCFA-producing flora and SCFA levels in the rat intestines (Zhang et al., 2012). Our results showed that the SCFA producers *Butyrivibrio, Eubacterium*, and *Clostridium* (Sakamoto et al., 2014; Xie et al., 2017; Mukherjee et al., 2020) were significantly enriched in the HFDBBR group, suggesting that SCFA-producing bacteria likely play an important role in the efficacy of berberine. Thus, we infer that the selective modulations of specific gut microbial phenotypes, particularly the enrichment of SCFA-producing bacteria, may participate in berberine-mediated alleviation of metabolic diseases in the host. However, some SCFA-producing bacteria, such as *Roseburia, Lachnospiraceae* unidentified species, *Coprococcus*, and *Clostridiales* unidentified species, were also enriched in the group of HFD. Although the results of functional prediction showed that the relative abundance of SCFA-producing genes in gut microbiota were significantly reduced in the HFD group, and BBR treatment could alleviate the reduction, whether berberine can increase the production of SCFA by regulating gut microbiota needs to be determined by measuring the content of fecal SCFA in the future. Notably, previous studies have shown that *Odoribacter splanchnicus* is negatively correlated with obesity (Etteberria et al., 2017), *Roseburia* is negatively correlated with the risk score of healthy high-risk gene carriers (Imhann et al., 2018), and *Oscillospira* is negatively correlated with body mass index and inflammation (Konikoff and Gophna, 2016). In a study demonstrating that sucralose alters the gut microbiota of mice and promotes liver inflammation, the abundance of *Dehalobacterium* was significantly reduced (Bain et al., 2017) and *AF12* was related to the beneficial effects of fecal bacteria transplantation (Lai et al., 2018). The baseline abundance of *Coprobacillus* correlated with COVID-19 severity (Zuo et al., 2020). *Proteus* can induce inflammatory responses in *vivo* and *in vitro* and may play a key role in the pathogenesis of Crohn’s disease (Zhang et al., 2020). *Trabulsella* and *Robinsoniella* are the most abundant species in infants delivered by cesarean section and cecal contents and mucosa, respectively (Linnenbrink et al., 2013; Kuang et al., 2016). However, we found that *Odoribacter, Roseburia, Oscillospira, Dehalobacterium*, and *AF12* were significantly enriched in the HFD group, whereas *Coprobacillus, Proteus, Trabulsella*, and *Robinsoniella* were significantly enriched in the HFDBBR group. The reasons for this need to be further explored. At the phylum level, significant differences in the relative abundance of Firmicutes and Bacteroidetes in gut microbiota have been observed between host groups with obesity and lean phenotypes (Turbaugh et al., 2006). In a rat study, significantly higher abundances of the Actinobacteria and Verrucomicrobia phyla were observed in the HFD group than in the NCD group, but this trend was completely reversed by berberine co-administration (Zhang et al., 2012). Similarly in this study, we found that HFD significantly increased the relative abundance of Firmicutes and Deferribacteres in the fecal flora of mice, but significantly reduced Bacteroidetes abundance. Furthermore, the relative abundance of Firmicutes in the fecal flora of mice in the HFD group was significantly reduced after berberine intervention, but was still higher than that in the normal control group. By comparison, the relative abundance of Bacteroidetes in the fecal flora was significantly increased, but was lower than that in the normal control group. A possible explanation for these observations may be that the Bacteroides phylum is positively correlated with LDL and HDL cholesterol levels, whereas the Firmicutes phylum is negatively correlated with total cholesterol and LDL and HDL cholesterol levels (Harata et al., 2017). This indicates that berberine intervention improves lipid metabolism. Previous studies on the Shannon–Wiener diversity index have revealed that berberine significantly decreases the bacterial diversity of the gut microbiota in both NCD- and HFD-fed rats (Zhang et al., 2012, 2015). However, our results indicated that HFD significantly increased the Shannon and Simpson indexes of the fecal flora of mice, but significantly reduced the number of OTU. These findings demonstrated that the composition of the fecal microbiota of mice treated with berberine and HFD was closer to that of mice fed on a normal diet. Furthermore, our study indicated that berberine can improve the gut microbiota disorder caused by HFD to some extent.

Although high-throughput sequencing of 16S rRNA gene has been widely used to analyze microbiota composition in various environments (Wu et al., 2017; Gong et al., 2021), it is difficult to distinguish microorganisms into species or strain level, which hinders a more detailed analysis of the function of gut microbes at species or strain level. Additionally, it is important to further exploit the gut microbiota-derived metabolites of berberine through metabolomics analysis. However, how to distinguish between gut microbiota-derived and host-derived metabolites is still challenging.

**CONCLUSION**

Our findings showed that berberine could improve chronic inflammatory metabolic syndrome induced by HFD to some extent and effectively improved the metabolism of high-fat food in mice, which correlated with the gut microbiota structure. This study may improve our understanding of host-microbe interactions during the treatment of metabolic diseases and provide useful insights into the action mechanism of berberine.

**DATA AVAILABILITY STATEMENT**

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://bigd.big.ac.cn/gsa/browse/CRA004451, CRA004451.

**ETHICS STATEMENT**

The animal study was reviewed and approved by the Animal Ethics Committee of the Qilu Normal University.
SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2021.752512/full#supplementary-material

AUTHOR CONTRIBUTIONS

JYL, JLL, and HS designed the experiments. JYL, JLL, and SW performed the animal experiments. JYL and JN conducted gut microbiota analysis. JYL, CZ, JJ, GW, and HS measured biochemical data and conducted immunohistochemical analysis. JYL and HS wrote the draft of the manuscript. All authors revised and approved the final version of the manuscript.

FUNDING

This work was funded by the Natural Science Foundation of Shandong Province (No. ZR2019MC020), National Undergraduate Innovation and Entrepreneurship Training Program (S202014276002), and Undergraduate Innovation and Entrepreneurship Project of Shandong Province (S202014276002).

REFERENCES

Aktan, F. (2004). iNOS-mediated nitric oxide production and its regulation. Crit. Rev. Immunol. 24, 659–635. doi: 10.1615/CritRevImmunol.v24.i5.003

Alferink, L. J. M., Radjabzadeh, D., Erler, N. S., Vojinovic, D., Medina-Gomez, C., Uitterlinden, A. G., et al. (2021). Microbiomics, metabolomics, predicted metagenomics and hepatic steatosis in a population-based study of 1335 adults. Hepatology 73, 968–982. doi: 10.1002/hep.31417

Anderson, M. J. (2001). A new method for non-parametric multivariate analysis of variance. Austr. Ecol. 26, 32–46. doi: 10.1111/1442-9993.01070.pp.x

Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., et al. (2004). The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. U.S.A. 101, 15718–15723. doi: 10.1073/pnas.0407076101

Bain, X. M., Chi, L., Gao, B., Tu, P. C., Ru, H., and Lu, K. (2017). Gut microbiota in mice regulates fat storage. Gut Microbiol. 30, 1761–1772. doi: 10.1007/s42255-018-0017-4

Boulangé, C. L., Neves, A. L., Chilloux, J., Nicholson, J. K., and Dumas, M. E. (2016). Impact of the gut microbiota on inflammation, obesity, and metabolic. Genome. Med. 8:42. doi: 10.1186/s13073-016-0303-2

Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L., Lee, J., et al. (2005). Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 11, 183–190. doi: 10.1038/nm1166

Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., et al. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761–1772. doi: 10.2337/db06-1491

Cani, P. D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A. M., Delzenne, N. M., et al. (2008). Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57, 1470–1481. doi: 10.2337/db07-1403

Cani, P. D., Hul, M. V., Lefort, C., Depommier, C., Rastelli, M., and Everard, A. (2019). Microbial regulation of organismal energy homeostasis. Nat. Metab. 1, 34–46. doi: 10.1038/s42255-018-0017-4

Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., et al. (2010). QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 7, 335–336. doi: 10.1038/nmeth.f.303

Chang, C. J., Lin, C. S., Lu, C. C., Martel, J., Ko, Y. F., Ojcius, D. M., et al. (2015). Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota. Nat. Commun. 6:7489. doi: 10.1038/ncomms8489

Choi, B. H., Ahn, I. S., Kim, Y. H., Park, J. M., Lee, S. Y., Hyun, C. K., et al. (2006). Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3-L1 adipocyte. Exp. Mol. Med. 38, 559–605. doi: 10.1038/emmm.2006.71

Dan, Z., Mao, X. H., Liu, Q. S., Guo, M. C., Zhuang, Y. Y., Liu, Z., et al. (2020). Altered gut microbiota profile is associated with abnormal metabolism activity of autism spectrum disorder. Gut Microbiol. 12:1246–1267. doi: 10.1080/19490976.2020.1747329

Delarue, J., and Magnan, C. (2007). Free fatty acids and insulin resistance. Curr. Opin. Clin. Nutr. Metab. Care 10, 142–148. doi: 10.1097/MCO.0b013e328042b9a0

Dixon, P. (2003). VEGAN, a package of R functions for community ecology. J. Veg. Sci. 14, 927–930. doi: 10.1111/j.1120-5229.2004.00382.x

Edgar, R. C. (2013). UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat. Methods 10, 996–998. doi: 10.1038/nmeth.2604

Etxeberria, U., Hijona, E., Aguirre, L., Milagro, F., Bujanda, L., Rimando, A. M., et al. (2017). Pertosilbene-induced changes in gut microbiota composition in relation to obesity. Mol. Nutr. Food Res. 65:1500096. doi: 10.1002/mnfr.201500906

Filipppo, D. D., Cavalieri, D., Paola, M. D., Ramazzotti, M., Poullet, J. B., Massart, S., et al. (2010). Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl. Acad. Sci. U.S.A. 107, 14691–14696. doi: 10.1073/pnas.1005963107

Gong, W., Gao, S., Zhu, Y., Wang, G., Zhang, K., Li, Z., et al. (2021). Effect of berberine on body weight in mice. J. Mol. Biol. 752512/full#supplementary-material

Gordon, S. (2016). Phagocytosis: an immunobiologic process. Immunity 44, 463–475. doi: 10.1016/j.immuni.2016.02.026

Gordon, S., and Pludekamm, A. (2017). Tissue macrophages: heterogeneity and functions. BMC Biol. 15:53. doi: 10.1186/s12915-017-0392-4

Greer, R. L., Dong, X. X., Moraes, A. C. F., Zieele, R. A., Fernandes, G. R., Peremyslova, E., et al. (2016). Akkermansia muciniphila mediates negative effects of IFNy on glucose metabolism-Akkermansia muciniphila. Nat. Commun. 7:13329. doi: 10.1038/ncomms13329

Guilliams, M., Dutertre, C. A., Scott, C. L., Govern, N. M., Sichien, D., Chakarov, S., et al. (2016). Unsupervised high-dimensional analysis aligns dendritic cells
across tissues and species. *Immunity* 45, 669–684. doi: 10.1016/j.immuni.2016.08.015
Guo, H. H., Chen, M., Zheng, W. S., Luo, Y., Li, C., Li, X. L., et al. (2019). Dual-stimuli-responsive gut microbiota-targeting berberine-CS/PT-NPs improved metabolic status in obese hamsters. *Adv. Funct. Mater.* 29, 18008197. doi: 10.1002/adfm.201808197
Hall, A. R., Yassour, M., Sauk, J., Garner, A., Jiang, X. F., Arthur, T., et al. (2017). A novel *Ruminococcus gravis* clade enriched in inflammatory bowel disease patients-lecture. *Genome Med.* 9:103. doi: 10.1186/s13073-017-0490-5
Hall, J. E., Carmo, J. M., Silva, A. A., Wang, Z., and Hall, M. E. (2015). Obesity-induced hypertension interaction of neurohumoral and renal mechanisms. *Circ. Res.* 116, 991–1006. doi: 10.1161/CircResaha.116.305697
Harata, G. K., Kumar, H., He, F., Miyazawa, K. J., Yoda, K., Kawase, M., et al. (2017). Probiotics modulate gut microbiota and health status in Japanese cedar pollinosis patients during the pollen season. *Eur. J. Nutr.* 56, 2245–2253. doi: 10.1007/s00394-016-1264-3
Haslam, D. W., and James, W. P. T. (2005). Obesity. *Lancet* 365, 669–678. doi: 10.1016/S0140-6736(05)66730-5
Harjola, V., Koivusalo, J., Harjula, A., Ruokonen, E., Mononen, T., Heiskanen, M., et al. (2017). Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. *Cell 137*, 635–646. doi: 10.1016/j.cell.2017.03.016
Helup, S., Brugiroux, S., Garzetti, D., Ring, D., Jochum, L. M., Beutler, M., et al. (2019). Mucipirinum scadleri antagonizes *Salmonella* virulence to protect host against colitis. *Cell Host Microbe* 25, 681–694. doi: 10.1016/j.chom.2019.03.004
Hill, A. A., Bolus, W. R., and Hasty, A. H. (2014). A decade of progress in adipose tissue macrophage biology. *ImmunoL Rev.* 262, 134–152. doi: 10.1111/imr.12216
Huang, R., Li, T., Ni, J., Fu, C., Huang, R., Li, Z., Cao, P., et al. (2021). Metabolic syndrome using 165 RNA marker gene sequences. *Nat. Biotechnol.* 31, 814–821. doi: 10.1038/nbt.2676
Larsen, C. M., Faulenbach, M., Vaag, A., Volund, A., Ehses, J. A., Seifert, B., et al. (2007). Interleukin-1 receptor antagonist in type 2 diabetes mellitus. *N. Engl. J. Med.* 356, 1517–1526. doi: 10.1056/NEJMoa065213
Leone, V., Gibbons, S. M., Martinez, K., Hutchison, A. L., Huang, E., Chah, C. M., et al. (2015). Effects of diurnal variation of gut microbes and high fat feeding on host circadian clock function and metabolism. *Cell Host Microbe* 17, 681–689. doi: 10.1016/j.chom.2015.03.006
Levy, M., Blacher, E., and Elinav, E. (2017). Microbiome, metabolites and host immunity. *Carr. Opin. Microbiol.* 35, 8–15. doi: 10.1016/j.mib.2016.10.003
Li, B., Zhu, W. L., and Chen, K. X. (2008). Advances in the study of berberine and its derivatives. *Acta Pharm. Sin.* 54, 773–787.
Li, C., Ai, G. X., Wang, Y. F., Lu, Q., Luo, C. D., Tan, L. H., et al. (2020). Oxyberberine, a novel gut microbiota-mediated metabolite of berberine, possesses superior anti-colitis effect: impact on intestinal epithelial barrier, gut microbiota profile and TLR4-MyD88- NF-κB pathway. *Pharmacol. Res.* 152:106403. doi: 10.1016/j.phrs.2019.106403
Lin, Y. G., Cai, Q. Y., Liang, B., Wu, L. Z., Zhuang, Y., He, Y. F., et al. (2019). Berberine, a traditional Chinese medicine, reduces inflammation in adipose tissue, polarizes M2 macrophages, and increases energy expenditure in mice fed a high-fat diet. *Med. Sci. Monit.* 25, 87–97. doi: 10.12659/MSM.911849
Linnenbrink, M., Wang, J., Hardouin, E. A., Künzel, S., Metzler, D., and Baines, J. F. (2013). The role of microbiome in shaping diversity of the intestinal microbiota in house mice. *Mol. Ecol.* 22, 1904–1916. doi: 10.1111/mec.12206
Livak, K. J., and Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. *Methods* 25, 402–408. doi: 10.1016/S1046-5228(01)00090-7
Lumeng, C. N., and Saltiel, A. R. (2011). Inflammatory links between obesity and metabolic disease. *J. Clin. Invest.* 121, 2111–2117. doi: 10.1172/JCI57132
Magoc, T., and Salzberg, S. L. (2011). FLASH: fast length adjustment of short reads to improve genome assemblies. *Bioinformatics* 27, 2957–2963. doi: 10.1093/bioinformatics/btr507
Matschiner, K. M., Vieira, A. T., Ng, A., Kranich, J., Sierro, F., Yu, D., et al. (2009). Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. *Nature* 461, 1282–1286. doi: 10.1038/nature08330
Menon, V. P., and Sudheer, A. R. (2007). Antioxidant and anti-inflammatory properties of curcumin. *Adv. Exp. Med. Biol.* 595, 105–125. doi: 10.1007/978-0-387-46401-5_3
Moncada, S., and Palmer, R. M. (2001). Biosynthesis and actions of nitric oxide. *Immunol. Lett.* 15, 16–19.
Moustafa, J. S. E. S., and Froguel, P. (2013). From obesity genetics to the future of personalized obesity therapy. *Nat. Rev. Endocrinol.* 9, 402–413. doi: 10.1038/nrendo.2013.57
Mozafari-Khosravi, H., Hosseinzadeh-Shamsi-Anar, M., Salami, M. A., Hadinedoushan, H., and Mozayan, M. R. (2012). Effects of a single post-partum injection of a high dose of vitamin D on glucose tolerance and insulin resistance in mothers with first-time gestational diabetes mellitus. *Diabetic Med.* 29, 36–42. doi: 10.1111/j.1464-5491.2011.03473.x
Muikherjee, A., Lordan, C., Ross, R. P., and Cotter, P. D. (2020). Gut microbes from the phylogenetically diverse genus *Eubacterium* and their various contributions to gut health. *Adv. Exp. Med. Biol.* 595, 105–125. doi: 10.1007/978-3-030-68377-7_3
Nagy, G., Raso, G. M., and Calignano, A. (2014). Role of innate immune response in non-alcoholic fatty liver disease: metabolic complications and therapeutic tools. *Front. Immunol.* 5, 177. doi: 10.3389/fimmu.2014.00177
Ni, J., Li, C., Huang, R., Li, Z., Li, S., Cao, P., et al. (2021). Metabolic syndrome cannot mask the changes of fecal microbiota compositions caused by primary
tripathi, p., tripathi, p., kashyap, l., and singh, v. (2007). the role of nitric oxide in inflammatory reactions. *immunol. med. microbiol*. 51, 443–452. doi: 10.1111/j.1174-695x.2007.00329.x

turnbaugh, p. j., ley, r. e., mahowald, m. a., magrini, v., mardis, e. r., and gordon, j. l. (2006). an obesity-associated gut microbiome with increased capacity for energy harvest. *nature* 444, 1027–1031. doi: 10.1038/nature05414

turner, j. r. (2009). intestinal mucosal barrier function in health and disease. *nat. rev. immunol.* 9, 799–809. doi: 10.1038/nri2563

velagpudi, v. r., hezaveh, r., reigstad, c. s., gopalacharyulu, p., yetukuru, l., islam, s., et al. (2010). the gut microbiota modulates host energy and lipid metabolism in mice. *j. lipid res.* 51, 1101–1112. doi: 10.1194/jlr.M002774

villinski, j., dumas, e., chai, h. b., pezzuto, j. m., angerhofer, c. k., gafner, s., et al. (2003). antibacterial activity and alkaloid content of berberis thunbergii, berberis vulgaris and hydrastis canadensis. *pharmac. biol*. 41, 551–557. doi: 10.1080/13880200390500768

wada, t., shimizu, m., toyama, t., hara, a., kaneko, s. c., and furuchi, k. (2012). clinical impact of albuminuria in diabetic nephropathy. *clin. exp. nephrol.* 16, 96–101. doi: 10.1007/s10115-011-0508-2

wang, k., liao, m. f., zhou, n., bao, l., ma, k., zheng, z. y., et al. (2019). parabacteroides distasonis modulates host metabolism and alleviates obesity and metabolic dysfunctions via production of succinate and secondary bile acids. *cell rep.* 26, 222–235. doi: 10.1016/j.celrep.2018.12.028

wang, q., garritty, g. m., tijdey, j. m., and cole, j. r. (2007). naive bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. *appl. environ. microbiol.* 73, 5261–5267. doi: 10.1128/AEM.00602-07

wang, y., wu, y. p., wang, b. k., xu, h., mei, x. q., xu, x. g., et al. (2019). bacillus amyloliquefaciens sc06 protects mice against high-fat diet-induced obesity and liver injury via regulating host metabolism and gut microbiota. *front. microbiol*. 10:1161. doi: 10.3389/fmicb.2019.01161

wei, x. y., tao, j. h., xiao, s. w., liang, s., shang, z. h., et al. (2018). xieixin tang improves the symptom of type 2 diabetic rats by modulation of the gut microbiota. *sci. rep.* 8:3685. doi: 10.1038/s41598-018-22094-2

wu, l., sun, q., and ni, j. (2017). not all of the rare operational taxonomic units (OTUs) play the same role in maintaining community stability. *appl. ecol. environ. res.* 15, 105–112. doi: 10.15666/aeer/1501_05112

wu, m., and wang, j. (2008). advance on study in anti-atherosclerosis mechanism of berberine. *chin. j. trad. chin. med. pharm.* 33, 2013–2016.

wu, m., wang, j., and liu, l. t. (2010). advance of studies on anti-atherosclerosis mechanism of berberine. *chin. j. intergr. med.* 16, 188–192. doi: 10.1007/s11655-010-0188-7

xiang, j., he, t., wang, p., xie, m., xiang, j., and ni, j. (2018). opportunistic pathogens are abundant in the gut of cultured giant spiny frog (Pau spinosa). *aqui. res.* 49, 2033–2041. doi: 10.1111/are.13660

xie, y. h., gao, q. y., cai, g. x., sun, x. m., zou, t. h., chen, h. m., et al. (2017). fecal crocidostocid symbiosis for noninvasive detection of early and advanced colorectal cancer: test and validation studies. *ebiomedicine* 25, 32–40. doi: 10.1016/j.ebiom.2017.10.005

xin, j. g., zeng, d., wang, h. s., ni, x. q., yi, d., pan, k. c., et al. (2014). preventing non-alcoholic fatty liver disease through *lactobacillus johnsonii* bs15 by attenuating inflammation and mitochondrial injury and improving gut environment in obese mice. *appl. microbiol. biotechnol.* 98, 6817–6829. doi: 10.1007/s00253-014-5752-1

yi, p., lu, f. e., xu, l. j., chen, g., deng, h., and wang, k. f. (2008). berberine reverses free-fatty-acid-induced insulin resistance in 3t3-l1 adipocytes through targeting ikkbeta. *world j. gastroenterol.* 14, 876–883. doi: 10.3748/wjg.v14.i8.847

yin, j., gao, z., liu, d., liu, z. j., and ye, j. p. (2008a). berberine improves glucose metabolism through induction of glycogenolysis. *am. j. physiol. endocrinol. metab.* 294, 148–156. doi: 10.1152/ajpendo.00211.2007

yin, j., xing, h., and ye, h. (2008b). efficacy of berberine in patients with type 2 diabetes mellitus. *metabolism* 57, 712–717. doi: 10.1016/j.metabol.2008.01.013

yoshimoto, s., luo, t. m., atarashi, k., sato, s., oyadomari, s., iwakura, y., et al. (2013). obesity-induced gut microbial metabolite promotes liver cancer through senesence oocyte. *nature 499*, 97–101. doi: 10.1038/nature12347

zhang, c. h., zhang, m. h., wang, s. y. h., ran, r. j., cao, y. f., hua, w. y., et al. (2010). interactions between gut microbiota, host genetics and diet relevant...
to development of metabolic syndromes in mice. ISME J. 4, 232–241. doi: 10.1038/ismej.2009.112
Zhang, H., Wei, J., Xue, R., Wu, J. D., Zhao, W., Wang, Z. Z., et al. (2010). Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 59, 285–292. doi: 10.1016/j.metabol.2009.07.029
Zhang, J. W., Hoedt, E. C., Liu, Q., Berendsen, E., Teh, J. J., Hamilton, A., et al. (2020). Elucidation of Proteus mirabilis as a key Bacterium in Crohn’s disease inflammation. Gastroenterology 160, 317–330.e11. doi: 10.1053/j.gastro.2020.09.036
Zhang, X., Zhao, Y. F., Xu, J., Xue, Z. S., Zhang, M. H., Pang, X. Y., et al. (2015). Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci. Rep. 5:14405. doi: 10.1038/srep14405
Zhang, X., Zhao, Y. F., Zhang, M. H., Pang, X. Y., Xu, J., Kang, C. Y., et al. (2012). Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One 7:e42529. doi: 10.1371/journal.pone.0042529
Zhang, Y. F., Li, X. Y., Zou, D. J., Liu, W., Yang, J. L., Zhu, N., et al. (2008). Treatment of type 2 diabetes and dyslipidemia with the natural plant Alkaloid Berberine. J. Clin. Endocrinol. Metab. 93, 2559–2565. doi: 10.1210/jc.2007-2404
Zhu, L. P., Han, J. K., Yuan, R. R., Xue, L., and Pang, W. Y. (2018). Berberine ameliorates diabetic nephropathy by inhibiting TLR4NF-κB pathway. Biol. Res. 51:9. doi: 10.1186/s40659-018-0157-8
Zuo, T., Zhang, F., Lui, G. C. Y., Yeoh, Y. K., Li, A. Y. L., Zhan, H., et al. (2020). Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology 159, 944–955. doi: 10.1053/j.gastro.2020.05.048

Conflict of Interest: JN is an employee of Guangdong Meilikang Bio-Science Ltd., China.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.